A Phase 1 Open-label Study Of 14c-labeled Talazoparib In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Talazoparib (Primary)
- Indications Adenocarcinoma; Breast cancer; Cervical cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 23 Aug 2017 Status changed from recruiting to completed.
- 23 May 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2017.
- 07 Mar 2017 New trial record